INIFY Laboratories AB (INIFY.OL) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · Norway
Price
5.32 NOK
Market cap
572.08 m NOK
P/E (2025)
–
P/S (2025)
26.00
Dividend yield
0.00 %
Net margin
-308.49 %
Return on equity (ROE)
-63.72 %
Return on assets (ROA)
-48.30 %
INIFY Laboratories AB financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 13.13 m SEK | 22.01 m SEK |
| Gross profit | 11.25 m SEK | 18.60 m SEK |
| Operating income | -52.99 m SEK | -69.66 m SEK |
| EBIT | -51.50 m SEK | -67.81 m SEK |
| Net income | -51.64 m SEK | -67.89 m SEK |
| Diluted EPS – continuing operations | -1.12 SEK | -0.85 SEK |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About INIFY Laboratories AB
INIFY Laboratories AB provides cancer diagnostics services in Sweden. It offers prostate cancer diagnostics services. The company was incorporated in 2021 and is based in Stockholm, Sweden.
More stocks
- Greenwood Sejahtera Tbk (GWSA.JK)
- Northeast Indiana Bancorp Inc (NIDB)
- JKG Land Bhd (6769.KL)
- JUPITER NEUROSCIENCES, INC. (JUNS)
- Highwood Asset Management Ltd (HAM.V)
- Mitre Realty Empreendimentos e Participações S.A (MTRE3.SA)
- Medinotec Inc. (MDNC)
- Permianville Royalty Trust (PVL)
- Atinum Investment Co. Ltd (021080.KQ)
- Skardin Industrial (3466.TWO)
- PRTR Group PCL (PRTR.BK)
- Nevgold Corp. (NAU.V)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.